The effect of anti-VEGF treatments for neovascular,exudative and inflammatory ocular diseases

The effect of anti-VEGF treatments for neovascular,exudative and inflammatory ocular diseases - The ocular effect of anti-VEGF treatments

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021589

Enrollment

3000

Registered

2016-04-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular diseases including neovascular, serous and inflammatory diseases

Interventions

Intravitreal anti-VEGF drugs (less than 2.0mg) Cataract and vitreous surgery Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Exudative or inflammatory ocular diseases including uveitis, macular diseases, retinal detachment, glaucoma, corneal diseases.

Exclusion criteria

Exclusion criteria: Children, and adults who can not understand this study or do not have a consciousness.

Design outcomes

Primary

Measure	Time frame
Visual prognosis including visual acuity after intravitreal anti-VEGF drugs	—

Secondary

Measure	Time frame
The intraocular inflammatory mediators including cytokines and chemokines The intraocular metabolomic profile including reactive polysulfide species.	—

Countries

Japan

Contacts

Public ContactFumihiko Nitta

Tohoku university graduate School of Medicine The department of ophthalmology

nitta@oph.med.tohoku.ac.jp0227177294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026